Amarin Corp Plc (AMRN)

[yellow_bluff]

Not sure if we get something big yet, but we are indeed potentially due for a label update.

I believe that right now, the reps are not even allowed to tell the docs about the Anchor trial, so this would be a huge upsell opportunity.

If there is any one single weakness to the AMRN story right is is that the Lovaza off label use is massive. While Lovaza script numbs are punching lower highs and lower lows on a weekly basis, they are entrenched and any off label use by Amrn is severely hampered right now by FDA guidance and the fact that FDA holds most all the cards right now.

A label change not only signals opening up of some off label potential, but also could signal that FDA wont convene a panel for Anchor. I know that some you on the board have stated that there is no need for a panel on an sNDA, and I hope that you are indeed right. I just know that mgt is trying to keep expecations low by indicating that they expect a panel.

yb